Rachel Klemovitch, Assistant Editor 06.03.24
Popular news items included company financial results, FDA approvals, and new patient studies.
Paragon 28 and Smith+Nephew both released their full-year 2024 guidance. Paragon 28 said its foot and ankle firm netted a record $61.1 million in revenue in its first quarter, a 17.4% growth over the prior year's Q1. Smith+Nephew recorded $1.39 billion in revenue in Q1 and forecasts sales to grow 5-6% in fiscal year 2024.
ODT released a column on challenges in FDA magnesium-based orthopedic devices, which are considered the next-generation biodegradable biomaterial for orthopedics.
OrthoXel gained 510(k) FDA clearance for its Vertex Hip Fracture Nail, which aims to enhance patient outcomes and streamline surgical procedures for stable results. FX Shoulder has received 510(k) clearance from the FDA for its six new full-wedge, augmented glenoid baseplates.
Stryker completed the first surgeries in Europe using its Infinity total ankle system with Adaptis and Everlast technology.
Sonex Health Inc. and The Institute of Advanced Ultrasound Guided Procedures have enrolled their first patient in its MISSION trial, which aims to assess carpal tunnel treatment.
Paragon 28 and Smith+Nephew both released their full-year 2024 guidance. Paragon 28 said its foot and ankle firm netted a record $61.1 million in revenue in its first quarter, a 17.4% growth over the prior year's Q1. Smith+Nephew recorded $1.39 billion in revenue in Q1 and forecasts sales to grow 5-6% in fiscal year 2024.
ODT released a column on challenges in FDA magnesium-based orthopedic devices, which are considered the next-generation biodegradable biomaterial for orthopedics.
OrthoXel gained 510(k) FDA clearance for its Vertex Hip Fracture Nail, which aims to enhance patient outcomes and streamline surgical procedures for stable results. FX Shoulder has received 510(k) clearance from the FDA for its six new full-wedge, augmented glenoid baseplates.
Stryker completed the first surgeries in Europe using its Infinity total ankle system with Adaptis and Everlast technology.
Sonex Health Inc. and The Institute of Advanced Ultrasound Guided Procedures have enrolled their first patient in its MISSION trial, which aims to assess carpal tunnel treatment.
- Paragon 28 Has Record Q1 Sales; Reaffirms Full-Year Guidance
- OrthoXel Receives FDA 510(k) Clearance for its Vertex Hip Fracture Nail
- Smith+Nephew Maintains Full-Year Guidance After Q1 Results
- Stryker Completes First European Surgeries with Everlast, Adaptis Total Ankles
- FDA Regulatory Challenges for Magnesium-Based Orthopedic Devices
- Orthobiologics Offer Patients a Healing Touch
- APEX Orthopedics Investments Launches for Foot & Ankle Industry
- FX Shoulder Wins FDA Nod for 6 Full-Wedge, Augmented Glenoid Baseplates
- Bioretec Hires Alan Donze as CEO
- First Patient Enrolled in Carpal Tunnel Release Treatment Study